The IGFBP5 Knockout PaTu 8988t Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population generated from the PaTu 8988t human pancreatic adenocarcinoma cell line. This product provides a loss-of-function model for the IGFBP5 gene, enabling investigation of its roles in cancer-relevant signaling networks, cellular phenotypes, and therapeutic responses. The polyclonal format comprises a heterogeneous pool of edited cells, offering a robust system for functional studies without the clonal selection constraints of monoclonal lines.
The PaTu 8988t host cell line was originally derived from a liver metastasis of a pancreatic ductal adenocarcinoma (PDAC) in a 64-year-old female patient. It exhibits a stable epithelial morphology and is widely employed as an in vitro model for studying PDAC biology, including metastatic progression, drug resistance, and tumor-stroma interactions. The metastatic origin of PaTu 8988t makes it particularly suitable for investigating molecular mechanisms underlying pancreatic cancer dissemination.
IGFBP5 encodes a secreted insulin-like growth factor-binding protein that modulates the bioavailability of IGF1 and IGF2, thereby regulating activation of the IGF1 receptor (IGF1R) and downstream signaling cascades. These primarily include the PI3K/AKT and MAPK/ERK pathways, which govern proliferation, survival, and metabolism. IGFBP5 also engages integrin-mediated adhesion (e.g., ITGAV/ITGB3) and interacts with extracellular matrix components such as fibronectin and thrombospondin-1. Its expression is transcriptionally regulated by TP53, TGFB1, retinoic acid, and steroid hormone receptors. Downstream, IGFBP5 influences AKT and ERK1/2 phosphorylation, the BAX/BCL2 apoptosis balance, p21 expression, and matrix metalloproteinase production, placing it at a nexus of growth factor signaling and cell fate decisions.
In the context of PaTu 8988t cells, disruption of IGFBP5 is expected to perturb the IGF signaling axis, potentially altering both PI3K/AKT and MAPK/ERK pathway activities. This modulation can affect cell proliferation, survival, and migratory/invasive behavior, processes that are critical in PDAC progression and metastasis. The polyclonal knockout population captures a spectrum of editing events, making it a valuable tool for dissecting the pleiotropic functions of IGFBP5 in a tumor-relevant background. Researchers can leverage this model to assess context-dependent tumor suppressor or promoter roles of IGFBP5 and to interrogate its impact on epithelial-mesenchymal transition and integrin-mediated interactions.
This polyclonal knockout model is suited for a wide array of applications in functional genomics and cancer biology, including dissection of IGFBP5-dependent signaling nodes and identification of synthetic lethal interactions in PDAC. Compatible assays include western blotting and phospho-specific analysis of AKT and ERK, RT-qPCR and RNA-seq for transcriptomic profiling, migration and invasion assays, apoptosis and colony formation assessments, and ELISA-based quantification of secreted IGFBPs. The cells also support co-immunoprecipitation studies of protein complexes and drug sensitivity screens. For additional technical details or to discuss customization, please contact Ascent Research.
